Evidence map›Paper›PMID 41791419›Full record

ArticleThe Journal of infectious diseases2026

Is it "Time to Eliminate" Time to Elimination of Symptoms as a Primary Trial End Point for Drugs Targeting Respiratory Viruses?

Joshua T Schiffer, Shadisadat Esmaeili, Katherine Owens, Michael Boeckh, Alpana Waghmare

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joshua T SchifferVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-2598-1621
Shadisadat EsmaeiliVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-3411-3834
Katherine OwensVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-5695-0203
Michael BoeckhVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-1538-7984
Alpana WaghmareVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-2268-9470

Funding

Development of an Oral Pan-Coronavirus Drug CocktailR01AI177512 · NIAID · UNIVERSITY OF WASHINGTON · PI STEPHEN J. POLYAK, Joshua Tisdell Schiffer · 2023 to 2026
$2.7M
National Institute of Allergies and Infectious Diseases R01AI77512NIAID NIH HHS R01 AI177512NIH
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical trialsend point selectioninfluenzarespiratory virusesSARS-CoV-2

Identifiers

PMID41791419
PMCPMC13148782

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.